Open AccessInterferon‐γ‐inducing Factor Gene Transfection into Lewis Lung Carcinoma Cells Reduces Tumorigenicity in vivo
Author(s) -
Fukumoto Hisao,
Nishio Makoto,
Nishio Kazuto,
Heike Yuji,
Arioka Hitoshi,
Kurokawa Hirokazu,
Ishida Tomoyuki,
Fukuoka Kazuya,
Nomoto Taisuke,
Ohe Yuichiro,
Saijo Nagahiro
Publication year - 1997
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1997.tb00409.x
Subject(s) - lewis lung carcinoma , in vivo , transfection , spleen , interferon , in vitro , biology , cancer research , microbiology and biotechnology , systemic administration , cell culture , cytokine , immunology , cancer , metastasis , biochemistry , genetics
To investigate the immunoregulatory effect of murine mterferon‐γ‐inducing factor (mIGIF), we transfected Lewis lung carcinoma (IXC) cells with a mammalian expression vector containing the mIGIF complementary DNA. The culture medium of the transfectant cells stimulated interferon‐γ (IFN‐γ) production by spleen cells in vitro in the presence of anti‐CD3 antibody and markedly potentiated the effect of interleukin‐12 (IL‐12) on IFN‐γ production by spleen cells. mIGIF transfectant cells showed reduction of tumorigenicity and induction of an in vivo immimo‐protective effect against the parental LLC cells. To examine the combined effect of systemic administration of recomhinant IL‐12 (rIL‐12) and local mIGIF on the tumorigenicity, mice were challenged with LLC or transfectant cells on day 0, and the tumor‐bearing mice were injected with 50 ng of rIL‐12 intraperitoneally from day 7 to 11. Systemic rIL‐12 showed an anti‐tumor effect. However, mIGIF gene expression did not potentiate this effect of systemic rIL‐12 in vivo.